Authors
Latest:
Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaBrian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.
Latest:
Interpretation and Clinical Implications of SEQUOIA Arm D Results in CLL/SLLExperts discuss the growing role of time-limited Bruton tyrosine kinase (BTK) inhibitor plus venetoclax therapy for high-risk chronic lymphocytic leukemia (CLL)—particularly in patients with deletion 17p—emphasizing the SEQUOIA R&D data that support flexible, minimal residual disease (MRD)-guided treatment durations and all-oral regimens as effective, convenient, and patient-centered options for achieving deep, durable responses.
Latest:
Future Directions: ctDNA Testing and Management of the CRC PatientExperts discuss how the evolving landscape of patient access to medical information challenges clinicians to stay current and communicate effectively, while emphasizing the expanding role of circulating tumor DNA testing across multiple cancers—offering more precise, personalized treatment guidance and paving the way for earlier, targeted interventions that improve patient outcomes and quality of life.
Latest:
Translating Rare Kidney Cancer Research into Clinical TrialsOne of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Latest:
Psycho-Oncology and the Relevance of a Biopsychosocial Screening ProgramRoutine biopsychosocial screening of a patient with metastatic renal cell cancer at the Centro de Câncer de Brasília improved symptom management and shrunk costs for both the patient and her caregivers.
Latest:
Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic ReviewDanazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
Latest:
Sequencing Bispecific Agents in a Rapidly Evolving Multiple Myeloma SpaceUsing bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Latest:
Fostering Multidisciplinary Care May Reduce Oncologist Workplace BurnoutJoseph C. Landolfi, DO, CPE, and Michele Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Latest:
Geriatric Assessment Finds Older and Younger Adults With PTCL Had Similar OutcomesTetiana Skrypets, MD, highlighted that older adults with PTCL may be treated as younger adults if they pass the geriatric assessment.
Latest:
Highlighting Insights From the Marginal Zone Lymphoma WorkshopClinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
Latest:
3 Things You Should Know About the Multimodal Treatment of SCLCHere are 3 things you should know about the multimodal treatment of patients with SCLC.
Latest:
Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic MelanomaThis clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
Latest:
Unmet Needs and Future Directions in CLLDrs Bishop and Bank close by outlining remaining unmet needs in CLL, emerging regimens, and hopes for the future of care.
Latest:
Investigational Treatment Approach Effective, Safe and Inexpensive in a Type of Prostate Cancer, Says ExpertThus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
Latest:
Treatment Response and Duration of Therapy in Transplant-Ineligible NDMMClosing out their module on transplant-ineligible NDMM management, expert panelists consider best practices regarding duration of therapy and adjustments to drug regimens.
Latest:
John Heymach, MD, PhD, Discusses the Use of Adjuvant Immunotherapy for Patients With NSCLCCancerNetwork® sat down with John Heymach, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk adjuvant immunotherapy for recurrence-free survival in resected non–small cell lung cancer.
Latest:
Jonathan Thompson, MD, MS, on AEs and Limitations Reported in the Phase 2 BGBC008 StudyThe trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI–refractory composite AXL (cAXL)–positive non–small cell lung cancer.
Latest:
Integrating PARP Inhibitors Into Advanced Prostate Cancer TherapeuticsExperts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
Latest:
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabRituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
Latest:
Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
